Skip to main content
. 2016 Feb 1;14(1):58–66. doi: 10.1089/adt.2015.672

Fig. 3.

Fig. 3.

(A) The statistics generated using the Synergy RunTool corresponding to the data generated as part of the discovery of probe ML302 (CID53362017). The bacteria tested was clinical isolate YMC07/8/B3323, an Acinetobacter spp. expressing VIM2. Fold reduction of the MIC of imipenem by ML302 is shown against this strain as 2×, 4×, 8×, and 16× fold. (B) These data were then archived in the Scripps database and also published to the PubChem web site (https://pubchem.ncbi.nlm.nih.gov/bioassay/624096#section=BioAssay-Target), which is available to the public. Note the maximum potentiation is listed for this and all other compounds published to the link above.